rethinkPeptides Search
Menu
Study breakdown

Lactoferricin Selectively Kills Cancer Cells While Sparing Normal Cells

In VitroPreliminary evidence
The takeaway

Bovine lactoferricin selectively induced apoptosis in leukemia and carcinoma cell lines while sparing normal lymphocytes and fibroblasts — demonstrating true cancer selectivity with clinical potential.

Key finding

Bovine lactoferricin induced apoptosis selectively in human leukemia (Jurkat, CEM) and carcinoma (MDA-MB-435) cell lines while sparing normal lymphocy

What the researchers found

Bovine lactoferricin induced apoptosis selectively in human leukemia (Jurkat, CEM) and carcinoma (MDA-MB-435) cell lines while sparing normal lymphocytes and fibroblasts — demonstrating cancer-selective cytotoxicity through membrane-dependent mechanisms.

Why it matters

Relevant for antimicrobial-peptides, cancer.

How the study worked

in-vitro study on antimicrobial-peptides, cancer.

What this study cannot tell us

See abstract.

How to read the evidence

preliminary evidence.

When this study was published

Published in 2005.

The bigger picture

Advances peptide research with clinical implications.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
Lactoferricin Selectively Kills Cancer Cells While Sparing Normal Cells
What was found?
Bovine lactoferricin selectively induced apoptosis in leukemia and carcinoma cell lines while sparing normal lymphocytes and fibroblasts — demonstrating true cancer selectivity with clinical potential.

Read the original research

Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines.

Molecular cancer therapeutics, 4(4), 612-24

Citation

Mader, Jamie S; Salsman, Jayme; Conrad, David M; Hoskin, David W. (2005). Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines.. Molecular cancer therapeutics, 4(4), 612-24.